Table 4.
Health economics module output: Effect of oseltamivir treatment intervention at 50% drug uptake on cost, life‐years (LY) and quality‐adjusted LY (QALY) by pandemic scenario. A cost per QALY gained of <0 indicates the new intervention is cost‐saving, a cost per QALY gained of >0 and <100 000 USD indicates the new intervention is cost effective, and a cost per QALY gained >100 000 USD indicates the new intervention is not cost effective
| Payer perspective | Societal perspective | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Comparators (Treatment vs. baseline) | Costs (A) (payer) | Costs (B) (payer – Baseline) | Costs (A) (societal) | Costs (B) (societal ‐ Baseline) | Death (A) | Death (B) | Δ Death (A–B) | Δ LYs (A–B) | Δ QALYs (A–B) | Cost per LY gained | Cost per QALY gained | Cost per LY gained | Cost per QALY gained |
| Low transmissibility and low severity | |||||||||||||
| 75 mg (A) vs. no treatment (B) | 9 225 251 | 42 578 018 | 12 998 947 | 106 995 703 | 27 | 439 | –412 | 399 | 430 | Cost‐saving | Cost‐saving | Cost‐saving | Cost‐saving |
| 150 mg (A) vs. 75 (B) mg | 14 835 713 | 9 225 251 | 17 109 649 | 12 998 947 | 16 | 27 | –11 | 10 | 11 | 546 753 | 515 260 | 400 598 | 377 524 |
| High transmissibility and high severity | |||||||||||||
| 75 mg (A) vs. no treatment (B) | 94 961 869 | 144 271 547 | 171 053 550 | 272 957 742 | 974 | 1591 | –617 | 598 | 629 | Cost‐saving | Cost‐saving | Cost‐saving | Cost‐saving |
| 150 mg (A) vs. 75 mg(B) | 81 019 150 | 94 961 869 | 139 379 855 | 171 053 550 | 747 | 974 | –227 | 220 | 227 | Cost‐saving | Cost‐saving | Cost‐saving | Cost‐saving |
| Low transmissibility and high severity | |||||||||||||
| 75 mg (A) vs. no treatment (B) | 11 450 971 | 79 213 439 | 15 596 974 | 149 869 617 | 53 | 874 | –821 | 795 | 828 | Cost‐saving | Cost‐saving | Cost‐saving | Cost‐saving |
| 150 mg (A) vs. 75 mg (B) | 16 176 877 | 11 450 971 | 18 675 157 | 15 596 974 | 32 | 53 | –21 | 20 | 21 | 231 280 | 223 797 | 150 642 | 145 768 |
| High transmissibility and low severity | |||||||||||||
| 75 mg (A) vs. no treatment (B) | 54 113 197 | 77 547 403 | 123 371 900 | 194 871 423 | 489 | 799 | –310 | 300 | 330 | Cost‐saving | Cost‐saving | Cost‐saving | Cost‐saving |
| 150 mg (A) vs. 75 mg (B) | 49 689 085 | 54 113 197 | 102 809 041 | 123 371 900 | 375 | 489 | –114 | 110 | 117 | Cost‐saving | Cost‐saving | Cost‐saving | Cost‐saving |
All costs are expressed in 2013 USD.
A, the alternative intervention; B, the baseline intervention.